GSK's Jemperli hits primary goal in rectal cancer trial
Positive interim results for its immunotherapy Jemperli in a phase II trial for dMMR/MSI-H locally advanced rectal cancer, raise the prospect that some patients could avoid chemotherapy, radiation and surgery.